塞尔帕替尼新

参考资料仅供科学研究，不可用于个人用途。

货号：BCP29047CAS号：2152628-33-4纯度：98%

规格	价格(CNY)	是否现货	购买咨询
1.00 g	￥1800.00	In-stock	购买咨询
2.00 g	￥3500.00	In-stock	购买咨询

在线咨询

大批量询价

全国免运费！免费咨询：400-099-8200 或手机联系：13472751340

* 必填项

请填妥以下表格,您将在一分钟内得到邮件机器人给你的报价。

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS号	2152628-33-4	货号	BCP29047
中文名	塞尔帕替尼
英文名	Selpercatinib
中文别名	塞卡替尼;
英文别名	LOXO-292;LOXO 292;LOXO292;
SMILES	CC(C)(COC1=CN2C(=C(C=N2)C#N)C(=C1)C3=CN=C(C=C3)N4CC5CC(C4)N5CC6=CN=C(C=C6)OC)O
化学名称
分子式	C29H31N7O3	分子量	525.25
纯度	98%	配送	惯例下常温包邮
产品描述	Selpercatinib is an orally bioavailable selective inhibitor of wild-type, mutant and fusion products involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), with potential antineoplastic activity. Upon oral administration, selpercatinib selectively binds to and targets wild-type RET as well as various RET mutants and RET-containing fusion products. This results in an inhibition of cell growth of tumors cells that exhibit increased RET activity. In addition, selpercatinib targets, binds to and inhibits vascular endothelial growth factor receptor 1 (VEGFR1) and 3 (VEGFR3), and fibroblast growth factor receptor 1 (FGFR1), 2 (FGFR2), and 3 (FGFR3). RET overexpression, activating mutations, and fusions result in the upregulation and/or overactivation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and progression of these cancers.

塞尔帕替尼 新